BiotechTube

ThermoDox + 5% Dextrose Solution

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

May 1, 2008 → Aug 1, 2016

NCT ID
NCT00617981

About ThermoDox + 5% Dextrose Solution

ThermoDox + 5% Dextrose Solution is a phase 3 stage product being developed by IMUNON for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00617981. Target conditions include Hepatocellular Carcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Hepatocellular Carcinoma were approved

Approved (5) Terminated (2) Active (14)
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty OintmentBayerApproved
✅Xenetix-CT perfusion imagingGuerbetApproved
✅Gadoterate meglumineGuerbetApproved
🔄Ramucirumab + PlaceboEli LillyPhase 3
🔄Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00617981Phase 3Completed

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
Ramucirumab + PlaceboEli LillyPhase 3
40
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
44
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
29
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
35
Tivantinib + PlaceboDaiichi SankyoPhase 3
40
OSI-906 + PlaceboAstellas PharmaPhase 2
27
Enzalutamide + PlaceboAstellas PharmaPhase 2
35
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
29
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
25
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
42
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
camrelizumab& apatinibSun PharmaceuticalPhase 2
31
LenvatinibEisaiPre-clinical
26
Lenvatinib PillEisaiPhase 2
39
Sorafenib + SorafenibEisaiPhase 1/2
32
LenvatinibEisaiPhase 2
42
Lenvatinib + NivolumabEisaiPhase 2
35